These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Structure-based drug design of novel ASK1 inhibitors using an integrated lead optimization strategy. Gibson TS; Johnson B; Fanjul A; Halkowycz P; Dougan DR; Cole D; Swann S Bioorg Med Chem Lett; 2017 Apr; 27(8):1709-1713. PubMed ID: 28291695 [TBL] [Abstract][Full Text] [Related]
7. Discovery of 2-arylquinazoline derivatives as a new class of ASK1 inhibitors. Monastyrskyi A; Bayle S; Quereda V; Grant W; Cameron M; Duckett D; Roush W Bioorg Med Chem Lett; 2018 Feb; 28(3):400-404. PubMed ID: 29277458 [TBL] [Abstract][Full Text] [Related]
9. Identification of novel ASK1 inhibitors using virtual screening. Okamoto M; Saito N; Kojima H; Okabe T; Takeda K; Ichijo H; Furuya T; Nagano T Bioorg Med Chem; 2011 Jan; 19(1):486-9. PubMed ID: 21134755 [TBL] [Abstract][Full Text] [Related]
10. Highly selective Janus kinase 3 inhibitors based on a pyrrolo[2,3-d]pyrimidine scaffold: evaluation of WO2013085802. Norman P Expert Opin Ther Pat; 2014 Jan; 24(1):121-5. PubMed ID: 24147573 [TBL] [Abstract][Full Text] [Related]
11. Discovery and development of ASK1 inhibitors. Brys R; Gibson K; Poljak T; Van Der Plas S; Amantini D Prog Med Chem; 2020; 59():101-179. PubMed ID: 32362327 [TBL] [Abstract][Full Text] [Related]
12. Identification of apoptosis signal-regulating kinase 1 (ASK1) inhibitors among the derivatives of benzothiazol-2-yl-3-hydroxy-5-phenyl-1,5-dihydro-pyrrol-2-one. Starosyla SA; Volynets GP; Lukashov SS; Gorbatiuk OB; Golub AG; Bdzhola VG; Yarmoluk SM Bioorg Med Chem; 2015 May; 23(10):2489-97. PubMed ID: 25882527 [TBL] [Abstract][Full Text] [Related]
13. Exploring novel indazole derivatives as ASK1 inhibitors: Design, synthesis, biological evaluation and docking studies. He M; Wang J; Deng W; Han X; Wang X; Pang L; Huang J; Lan P; Wang T; Wang Z Bioorg Chem; 2024 Jun; 147():107391. PubMed ID: 38677010 [TBL] [Abstract][Full Text] [Related]
14. [Identification of low-molecular inhibitors of proteinase ASK1]. Volynets GP; Bdzhola VG; Kukharenko OP; Iarmoliuk SM Ukr Biokhim Zh (1999); 2010; 82(5):41-50. PubMed ID: 21674960 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of WO2012032067 and WO2012055846: two selective PI3Kδ inhibitors, which is GSK-2269557? Norman P Expert Opin Ther Pat; 2012 Aug; 22(8):965-70. PubMed ID: 22765651 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of WO2012037132 - a novel scaffold for selective JAK1 inhibition. Norman P Expert Opin Ther Pat; 2012 Sep; 22(9):1105-9. PubMed ID: 22812580 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of WO2012037204 and WO2012037226: Exelixis' selective PI3Kδ inhibitors; the basis of a US$251 million deal. Norman P Expert Opin Ther Pat; 2012 Aug; 22(8):971-6. PubMed ID: 22768915 [TBL] [Abstract][Full Text] [Related]
18. Identification of 3H-naphtho[1,2,3-de]quinoline-2,7-diones as inhibitors of apoptosis signal-regulating kinase 1 (ASK1). Volynets GP; Chekanov MO; Synyugin AR; Golub AG; Kukharenko OP; Bdzhola VG; Yarmoluk SM J Med Chem; 2011 Apr; 54(8):2680-6. PubMed ID: 21449566 [TBL] [Abstract][Full Text] [Related]
19. Pharmacophore modeling of diverse classes of p38 MAP kinase inhibitors. Sarma R; Sinha S; Ravikumar M; Kishore Kumar M; Mahmood SK Eur J Med Chem; 2008 Dec; 43(12):2870-6. PubMed ID: 18406015 [TBL] [Abstract][Full Text] [Related]
20. Development of a novel fluorescent probe for fluorescence correlation spectroscopic detection of kinase inhibitors. Kawaguchi M; Terai T; Utata R; Kato M; Tsuganezawa K; Tanaka A; Kojima H; Okabe T; Nagano T Bioorg Med Chem Lett; 2008 Jul; 18(13):3752-5. PubMed ID: 18524589 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]